blood pressure high; tachycardia; cardiac discomfort; this is a spontaneous report received from a contactable reporter(s) (other hcp) from the regulatory authority. regulatory number: is-ra-7302 (ra). a 53 year-old female patient received bnt162b2 (comirnaty), administration date 20mar2021 (batch/lot number: unknown) as dose 1, single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. the following information was reported: hypertension (medically significant) with onset 08apr2021, outcome "recovered" (2021), described as "blood pressure high"; tachycardia (medically significant) with onset 08apr2021, outcome "recovered" (2021), described as "tachycardia"; cardiac discomfort (medically significant) with onset 08apr2021, outcome "recovered" (2021), described as "cardiac discomfort". the patient underwent the following laboratory tests and procedures: blood pressure measurement: 160/90. reporter comment: after first dose of pfizer, patient experienced cardiac discomfort and blood pressure was taken and was elevated (160/90). after second dose, patient experienced tachycardia, symptoms were ongoing for 3 months. went to see a doctor, tachycardia was seen there. it was reported that the patient underwent a heart check and everything was normal. additional information: the onset latency of the events hypertension and cardiac discomfort was reported as 19 days.; reporter's comments: after first dose of pfizer, patient experienced cardiac discomfort and blood pressure was taken and was elevated (160/90). after second dose, patient experienced tachycardia, symptoms were ongoing for 3 months. went to see a doctor, tachycardia was seen there. it was reported that the patient underwent a heart check and everything was normal. sender's comments: linked report(s) : is-pfizer inc-202200304307 same patient/product, different event/dose